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ABSTRACT
Introduction MRI and MR spectroscopy (MRS) provide 
early biomarkers of brain injury and treatment response 
in neonates with hypoxic- ischaemic encephalopathy). 
Still, there are challenges to incorporating neuroimaging 
biomarkers into multisite randomised controlled trials. In 
this paper, we provide the rationale for incorporating MRI 
and MRS biomarkers into the multisite, phase III high- dose 
erythropoietin for asphyxia and encephalopathy (HEAL) 
Trial, the MRI/S protocol and describe the strategies used 
for harmonisation across multiple MRI platforms.
Methods and analysis Neonates with moderate or 
severe encephalopathy enrolled in the multisite HEAL 
trial undergo MRI and MRS between 96 and 144 hours of 
age using standardised neuroimaging protocols. MRI and 
MRS data are processed centrally and used to determine 
a brain injury score and quantitative measures of lactate 
and n- acetylaspartate. Harmonisation is achieved through 
standardisation—thereby reducing intrasite and intersite 
variance, real- time quality assurance monitoring and 
phantom scans.
Ethics and dissemination IRB approval was obtained at 
each participating site and written consent obtained from 
parents prior to participation in HEAL. Additional oversight 
is provided by an National Institutes of Health- appointed 
data safety monitoring board and medical monitor.
Trial registration number NCT02811263; Pre-result.
INTRODUCTION
Neonatal hypoxic- ischaemic encephalopathy 
(HIE) is a major cause of death and neuro-
developmental disability, contributing to 
almost a quarter of neonatal deaths world-
wide.1–3 Therapeutic hypothermia (TH) is 
the first empirically supported therapy for 
neuroprotection in neonates with HIE.2 3 
Still, even with TH, 40%–50% of neonates die 
or develop moderate to severe neurodevelop-
mental impairments.2 3 To improve outcomes, 
efforts are focused on the development and 
clinical translation of adjuvant neuroprotec-
tive therapies.
The high- dose erythropoietin (Epo) for 
asphyxia and encephalopathy (HEAL) trial 
(NCT02811263) is a multicentre, randomised, 
double- blind, placebo- controlled, phase 
Strengths and limitations of this study
 ► This study will be the first to determine if high- dose 
erythropoietin administered to infants with moderate 
to severe neonatal hypoxic- ischaemic encephalopa-
thy (HIE) reduces brain injury as measured by quan-
titative MRI and MR spectroscopy (MRS) biomarkers.
 ► MRI and MRS data are collected prospectively, using 
standardised MRI and MRS protocols, with quality 
assurance and oversight provided by the high- dose 
erythropoietin for asphyxia and encephalopathy 
neuroimaging core.
 ► Findings will clarify treatment effects of erythropoi-
etin in neonates with HIE and will provide further 
support of efficacy.
 ► Limitations include the use of nine different MRI 
platforms and clinical workflow, which poses chal-
lenges for harmonisation and for collecting quan-
titative data, including MRS files. Techniques for 
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III clinical trial designed to test the efficacy of Epo for 
neuroprotection as an adjuvant to TH in neonates with 
moderate to severe HIE.4 Preclinical studies have shown 
that Epo induces multiple neuroprotective responses 
that act synergistically to reduce brain injury, promote 
repair and improve neurological outcomes after hypoxia- 
ischaemia.5 Recent phase I/II clinical trials support the 
safety of high- dose Epo and potential efficacy for neuro-
protection in neonates with HIE.6–9 In the HEAL trial, 500 
neonates with moderate or severe HIE undergoing TH 
will be randomised to receive Epo (1000 U/kg) or placebo 
on days 1, 2, 3, 4 and 7 of life. The primary endpoint is 
the composite of death or neurodevelopmental impair-
ment at 24 months of age. As a secondary aim, HEAL will 
determine whether Epo decreases the severity of brain 
injury by MRI and MR spectroscopy (MRS). In this paper, 
we provide the rationale for incorporating MRI and MRS 
biomarkers into the multisite, phase III HEAL trial, the 
MRI/S protocol and describe the strategies used for 
harmonisation across multiple MRI platforms.
Neuroimaging biomarkers of neonatal HIE
Neuroimaging biomarkers provide information 
regarding the nature and severity of the precipitating 
insult, timing and prognosis. This is implied by the locus 
and extent of injury and the signal characteristics on 
T1- weighted (T1w), T2- weighted (T2w) and diffusion- 
weighted imaging (DWI). Additionally, advanced tech-
niques such as MRS provide biochemical information 
regarding energy homoeostasis and injury progression, 
while diffusion tensor imaging (DTI) provides informa-
tion regarding microstructure and connectivity.
Patterns of injury
There are two hallmark patterns of injury associated 
with neonatal HIE: a central pattern involving injury to 
the deep grey nuclei (ventrolateral thalamus and poste-
rior putamen) and perirolandic (paracentral) cortex, 
with or without concomitant injury to the brainstem 
and a peripheral pattern, involving injury to the white 
matter and/or overlying cortex in a parasagittal distri-
bution along the vascular borderzone (watershed terri-
tory). These patterns are similar to the patterns of injury 
observed experimentally in primates following ‘near 
total’ and ‘prolonged partial’ asphyxia, respectively.10–14 
Other commonly observed findings in neonates with 
HIE include punctate white matter lesions, focal lesions 
(including strokes) and haemorrhages (intraventricular, 
intraparenchymal and extra- axial), as well as ‘normal’ 
MRIs (no apparent injury).15–20
Epidemiological neuroimaging data are limited, and 
thus, the prevalence of various injury patterns in neonates 
with mild, moderate or severe HIE, as classified by Sarnat 
Stage, is not known. Multiple studies have investigated 
whether the pattern of injury varies by maternal–fetal 
factors, including sentinel events during delivery and 
placental function; however, a consistent pattern has 
yet to emerge. Several studies have shown that sentinel 
events were associated with an increased risk of injury 
to the thalamus/basal ganglia and/or cortex and white 
matter21 22; however, the opposite has also been found.23 
Likewise, placental abnormalities have been associated 
with HIE24–26; however, there has been inconsistency with 
regard to which placental findings are associated with 
which pattern(s) of injury.27–30
Timing and evolution of HIE brain injury
HIE injury evolves over days, and serial imaging has 
demonstrated this evolution is associated with varying 
signal abnormalities on T1w and T2w MRI, DWI and 
MRS. Acutely, injury appears as areas of restricted diffu-
sion on Trace- DWI and apparent diffusion coefficient 
(ADC) maps. Quantitative measurements obtained in 
neonates with HIE show that ADC values reach their 
nadir 2–3 days after birth and rise thereafter, pseudonor-
malising at approximately 1 week after birth.31 32 These 
curves are similar at 1.5 and 3T; however, measured ADC 
values are inversely related to b- value, and higher b- values 
(≥1000 s/mm2) are more sensitive for detecting acute 
injury.33 34 TH augments the ADC curve producing lower 
ADC values and may extend the time window for pseudo-
normalisation to as late as 8–10 days of age.35
Conventional MRI demonstrates parallel signal 
changes. Acutely, oedema appears as areas of low signal 
and high signal on T1w and T2w MRI, respectively. These 
areas may show corresponding low ADC values indi-
cating cytotoxic oedema (cell swelling). As injury evolves, 
focal areas of T1 hyperintensity with correspondent T2 
hypointensity begin to appear in the deep grey and/or 
cerebral cortex, especially, in the ventrolateral thalamus, 
posterolateral putamen and perirolandic cortex. Addi-
tionally, T1w and T2w imaging may show disruption of 
the normal cortical ribbon, particularly in borderzone 
(watershed) regions or in the vicinity of other focal inju-
ries (eg, infarcts, contusions).
MRS demonstrates comparable changes in metabo-
lite concentrations during the first and second week 
after birth. Acutely, there is a rise in lactate, a marker 
of anerobic metabolism; however, lactate peaks during 
the first week, followed by a rise in lipids, which are only 
detectable at short echo time.36 By contrast, n- acetyl-
aspartate (NAA), a marker of neuronal mitochondrial 
metabolism, declines during the first few days and then 
remains lower among HIE infants with brain injury.32 37–39 
Other metabolites show transient changes following HIE 
including phosphocreatine, myoinositol, glutamine and 
choline.40–43
In conjunction with evolving signal abnormalities on 
T1w, T2w, DWI and MRS, serial imaging has also shown 
that the locus of injury may evolve during the first week. 
This is especially common among infants with injury 
to the deep grey matter who often demonstrate injury 
localised to the ventrolateral thalamus +- dorsal brain-
stem on early scans (1–3 days of age), followed by more 
widespread injury in the deep grey nuclei (particularly 
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scans (4+ days).15 32 44 Moreover, as injury evolves, areas of 
Wallerian degeneration often appear on DWI, including 
in the posterior limb of the internal capsule (PLIC), sple-
nium and brainstem.15 32
MRI as a prognostic biomarker
MRI is widely employed clinically as a prognostic 
biomarker, and several semiquantitative scoring systems 
have been developed for use in clinical research.16 17 20 45–49 
Most of these systems place greater weight on injury to 
the grey matter (thalamus, basal ganglia and perirolandic 
cortex) as these findings have been most consistently asso-
ciated with adverse outcomes, including death and neuro-
developmental impairment.16 20 45–49 However, scoring 
systems differ with regard to how they quantify severity, 
with some inferring severity from the locus of the injury 
alone16 39 45 while others infer severity from the locus and 
extent of signal abnormality.20 48 Several yield information 
regarding pattern of injury.16 44 45 None provide quanti-
tative information regarding stage (ie, acute, subacute, 
chronic) based on the evolving signal abnormalities on 
MRI.
Several studies have assessed the validity of the 
semiquantitative MRI scores in single centre45 48 and 
multicentre studies.16 20 39 47 50 51 These studies have 
demonstrated variable accuracy for predicting death or 
neurodevelopmental impairment at follow- up, ranging 
from area under the curve (AUC) 0.7–0.99.20 37 48 51 Some 
of this variability in predictive accuracy may be accounted 
for by the timing of the MRI exams and the sequences 
employed. Several studies have suggested that early scans 
(<1 week) may provide better sensitivity while later scans 
provide better specificity.51 52
Multiple studies have shown that MRS enhances the 
predictive accuracy of MRI20 37 51 and several studies have 
suggested that MRS may provide the highest predictive 
accuracy of all MRI biomarkers.39 51 By contrast, quantita-
tive ADC measurements have poor prognostic accuracy,51 
likely due to pseudonormalisation, as discussed above.
Neuroimaging biomarkers in prior randomised controlled 
trials for neuroprotection
MRI was included as a secondary outcome in three 
previous phase III randomised controlled trials (RCTs) 
for TH: the NICHD Neonatal Research Network (NRN) 
Trial (2005),16 the Total Body Hypothermia for Neonatal 
Encephalopathy (TOBY) Trial (2009)17 and the Infant 
Cooling Evaluation (ICE) Trial (2011).47 All three trials 
found that TH was associated with less injury on MRI. 
Furthermore, the sensitivity and specificity of the MRI 
biomarkers for predicting adverse outcome did not 
differ between neonates who received TH and those who 
received normothermia (NT), indicating that TH did not 
alter the prognostic value of MRI in neonates with HIE.
However, the MRI results from the three cooling trials 
varied in several important aspects. First, although TH 
was associated with less brain injury on MRI in each trial, 
the nature of the effect varied. In the TOBY Trial, TH 
was associated with a reduction in signal abnormalities 
in the basal ganglia/thalamus (BGT) (OR 0·36, 95% CI 
0·15 to 0·84; p=0·02), white matter (0·30, 0·12 to 0·77; 
p=0·01),and PLIC (0·38, 0·17 to 0·85; p=0·02).17 In 
contrast, TH was not associated with a significant reduc-
tion in BGT injury in either the NICHD NRN or ICE trial, 
but was associated with a significant reduction in injury to 
the cortex and underlying white matter.16 47
The inconsistent MRI findings in the three cooling 
trials are likely due, at least in part, to differences in study 
design, including inclusion criteria, cooling technology 
and neuroimaging methods. Moreover, only a subset 
of patients in each trial had analyzable MRI data, and 
both the proportion of patients in the MRI subanalyses, 
which ranged from 40% to 65%, and relative proportion 
assigned to each treatment group (TH vs NT) varied 
across trials.16 17 47 Likewise, the MRI protocols differed 
between trials (e.g., with or without DWI) as did the 
timing of imaging, with mean age ranging from 647 to 15 
days.16 Consistent with the variability in the neuroimaging 
methods, the sensitivity and specificity of MRI biomarkers 
as predictors of outcome varied substantially across trials, 
with the highest sensitivity—but low specificity—in the 
NICHD NRN trial, and the highest specificity—but low 
sensitivity—in ICE.16 17 47 This variability limits any conclu-
sions regarding differences in neuroimaging outcomes 
across the three TH trials and points to the necessity of 
standardisation and harmonisation.
Special considerations for MRS
Incorporating MRS into multisite trials poses additional 
challenges beyond those encountered for conventional 
MRI. Many hospitals do not routinely acquire MRS in 
neonates with HIE as MRS requires specific software pack-
ages, which may not have been purchased. MRS acquisi-
tion is also more technically demanding due to its low 
signal to noise ratio (SNR) compared with conventional 
MRI.53 There are also challenges associated with detection 
of lactate and other j- coupled metabolites that must be 
addressed at acquisition and/or postprocessing in order 
to avoid known pitfalls.54 Likewise, MRS analysis and 
interpretation are more complex than conventional MRI 
and require expert knowledge beyond core competence 
in diagnostic radiology. Last, MRS has its own separate 
billing code, and reimbursement is poor, often requiring 
preauthorisation. Thus, although recommended by the 
American College of Obstetrics and Gynecology task 
force on Neonatal Encephalopathy and endorsed by the 
American Academy of Pediatrics for assessment of brain 
injury in neonatal HIE,55 MRS usage lags behind MRI.
MRS was not systematically incorporated into any prior 
multicentre, phase III cooling trials for HIE, but it has 
been incorporated into single- centre32 41–43 56–58 and 
multicentre observational studies39 59 as well as several 
recent phase I/II RCTs.60 61 The sensitivity and specificity 
of MRS for predicting outcome is not affected by TH, 
making it suitable for use as a prognostic biomarker in 
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the reliability and diagnostic accuracy of MRS biomarkers 
may be affected by the timing of exam, sequence param-
eters (short echo vs long echo), region sampled (BGT vs 
white matter), postprocessing methods (ratios vs absolute 
quantitation) and the precise metabolites chosen (eg, 
lactate, NAA, creatine, choline).39 51 52
METHODS
In this section, we present the HEAL Neuroimaging 
Protocol in accordance with the Standard Protocol Items: 
Recommendations for Interventional Trials (SPIRIT) 
reporting guidelines.65
Study design
The HEAL trial is a multicentre, phase III, randomised, 
double- blind, placebo- controlled trial involving 500 
neonates, ≥36 weeks gestational age with moderate to 
severe HIE who are undergoing TH. Treatment allocation 
(Epo or placebo) is parallel (1:1), stratified by site and 
HIE severity. Parents, participants and study personnel—
including the Neuroimaging Core—are blinded to the 
treatment group. For further details regarding the HEAL 
trial, please see online supplemental appendix 1 and also 
Juul et al.4
MRI and MRS data are obtained at 4–5 days of age as 
part of routine clinical care, using a standardised MRI 
protocol. Neuroimaging data are then analysed centrally 
by the HEAL Neuroimaging Core. Details regarding 
acquisition, data transfer, data processing and analyses 
are provided in the next section.
Patient and public involvement
This study was designed by the HEAL Study Group. There 
is no parental advisory board. Results will be disseminated 
to other physicians via academic medical conferences and 
to the public at large via standard press releases.
Study locations
The HEAL trial is being carried out across a network of 
17 study sites, using 9 MR platforms (table 1). Five of 
the sites include two or more enrolling hospitals. Each 
of the participating hospitals has a 3T MR system, with 
the exception of one hospital, which is using a 1.5T MR 
system and a dedicated neonatal head coil.
MRI and MRS sequences and sequence parameters
Prior to the start of HEAL enrolment, detailed MRI 
protocols were developed for each MRI platform. 
During the preparatory phase, we compared different 
sequences and sequence parameters across platforms in 
order to maximise consistency in image contrast, resolu-
tion and SNR across platforms using US Food and Drug 
Administration- approved product sequences. The final 
protocol is presented in table 2 (see also figures 1 and 
2, eg, images). One limitation is that we were not able 
to find an optimal solution for a 3 dimensions (3D) T2w 
sequence. Therefore, we used a 2D sequence, with the 
in- plane resolution matched to our 3D T1w sequence and 
slice thickness at 2 mm (no gap) in alignment with our 
DTI sequence.
The MRS protocol includes both short echo (TE 35) 
and long- echo (TE 288) acquisitions. Furthermore, the 
decision to use TE 288 over TE 144 mitigates a known 
pitfall with lactate at 3T, namely the attenuation and even 
absence of signal at TE 144 due to anomalous j- coupling,54 
while the short echo (TE 35) acquisitions allow for quan-
titation of additional metabolites, including glutamate, 
glutamine and lipids.
Timing of brain MRI and MRS
The target window for the HEAL MRI is day 4 or 5 after 
birth (between 96 and 144 hours of age). This window 
corresponds to a period of maximal sensitivity and spec-
ificity for MRI and MRS51 when abnormal DWI/ADC 
signal is maximised51 57 and risk of pseudonormalisation 
is minimised.31 44 Furthermore, this timing is compatible 
with current clinical practice and provides information 
to guide medical management including decisions about 
redirection of care. For those infants who are not clinically 
stable for MRI during this window, MRIs are obtained as 
soon after the infant becomes clinically stable as possible.
Use of sedation
Because HEAL MRI scans are performed as part of routine 
clinical care, the use of sedation is determined locally by 
the attending physicians on a case- by- case basis. Given 
concerns regarding possible neurotoxic effects of anaes-
thetic drugs,66 every effort has been made to facilitate 
non- sedated imaging whenever possible. To determine 
whether sedatives effect MRS metabolite concentrations, 
all psychoactive medications administered within 4 hours 
of the examination are recorded in the HEAL database.
Anonymisation and data transfer
Anonymisation and transfer of neuroimaging data is 
facilitated by using a secure, Health Information Porta-
bility and Accountability Act (HIPAA)- compliant, cloud- 
based service (Ambra Health, New York, New York, USA). 
Because raw quantitative MRS data are not compatible 
with clinical PACS systems, we developed specific proto-
cols to transfer these data from the MR scanner in stan-
dard DICOM (Siemens), enhanced DICOM (Philips), 
P- files (GE) other file formats (eg, SPAR/SDAT, RDA), as 
needed. Furthermore, although the cloud- based service 
provides anonymisation on upload to the HEAL Neuro-
imaging Core, uploading the raw MRS data requires 
anonymisation prior to or during export from the MR 
scanner as detailed in table 3.
Data processing: MRI
The primary HEAL neuroimaging outcome measures 
is the total MRI injury score based on a previously vali-
dated MRI scoring system for HIE.48 This score indicates 
the extent of signal abnormality (ie, 0=none, 1 ≤25%, 
2=25%–50%, 3 ≥50%) for each of the deep grey nuclei, 
PLIC, cerebral cortex, white matter and cerebellum, as 
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each sequence as shown in table 4. ‘Signal abnormality’ 
is defined qualitatively as either abnormally low or high 
signal on T1w and T2w images or areas of restricted 
diffusion on Trace- weighted or ADC images calculated 
from the DTI sequence. We do not employ a quantita-
tive threshold for ADC, consistent with the previously 
validated scoring system.7 48 Areas with high ADC are not 
scored as injury for the DTI images, which is designed 
to measure acute injury; however, correspondent areas of 
low and/or high signal on the T1w and/or T2w images 
are scored.
For each ROI, injury is scored qualitatively for each 
sequence on a 4- point scale based on the extent of signal 
abnormality (0=none, 1 = <25%, 2=25%–50%, 3 ≥50%), 
except for the brainstem which is scored on a 3- point 
scale (0=none; 1=focal; 2=multifocal/widespread).
To compute the MRI injury score, each scan is reviewed 
independently by two of three experienced readers 
(AMM, JLW and RCM), who are blinded to the infant’s 
clinical course, treatment assignment and MRS find-
ings. After the primary review, each scan undergoes final 
consensus review during which any discrepancies are 
reviewed by all three reviewers and resolved by consensus. 
The individual and consensus scores are then classified as 
none (total=0), mild (1–11), moderate (12–32) or severe 
(33–138), in accordance with the previously validated 
MRI injury classification.48 Inter- rater reliability between 
the three independent readers will be determined for 
Table 1 Participating sites
Site Hospital MR manufacturer Model Software
On- site support 
for HEAL
Seattle, WA*†‡ Seattle Children’s Hospital Siemens Prisma E11 Physicist
Columbus, OH Nationwide Children’s Hospital Siemens Skyra E11 Physicist
Dallas, TX Parkland Hospital Siemens Skyra E11 MR Technologist
Indianapolis, IN Riley Hospital for Children Siemens Skyra E11 MR Technologist
Minneapolis- St. Paul, 
MN‡
Children’s Hospital and Clinics of 
Minnesota: Minneapolis
Siemens Skyra E11 MR Technologist
Minneapolis- St. Paul, 
MN‡
Children’s Hospital and Clinics of 
Minnesota: St. Paul
Siemens Skyra E11 MR Technologist
Philadelphia, PA Children’s Hospital of Philadelphia Siemens Skyra E11 Physicist
Pittsburgh, PA‡§ Children’s Hospital of Pittsburgh of 
UPMC
Siemens Skyra E11 Physicist
Fort Worth, TX Cook Children’s Medical Center Siemens Verio B19 MR Technologist
San Antonio, TX‡ Children’s Hospital of San Antonio Siemens Verio D13 MR Technologist
San Antonio, TX‡ Methodist Children’s Hospital Siemens Trio B17 MR Technologist
St. Louis, MO§ Washington University Medical Center/
St. Louis Children’s Hospital
Siemens Trio B17 Physicist
Nashville, TN Vanderbilt University Medical Center Philips Achieva 3.2 MR Technologist
Seattle, WA*,†‡ University of Washington Medical 
Center
Philips Achieva 5.3 Physicist
Cincinnati, OH Cincinnati Children’s Hospital Medical 
Center
Philips Ingenia 5.3 Physicist
Los Angeles, CA§ Children’s Hospital Los Angeles Philips Ingenia 5.1.7 Physicist
San Francisco, CA*§ UCSF Benioff Children’s Hospital GE 750 DV25 Physicist
Stanford, CA Stanford University Medical Center GE 750 DV26 Physicist
Washington, DC Children’s National Medical Center GE 750 DV26 Physicist
Salt Lake City, UT Primary Children’s Medical Center/Univ. 
of Utah
GE Architect DV27 MR Technologist
Pittsburgh, PA‡ UPMC Magee Women’s Hospital GE HDx¶ DV24 Physicist
*Clinical Coordinating Centre.
†Data Coordinating Centre.
‡Denotes sites with more than one enrolling hospital.
§Neuroimaging core.
¶1.5T MR system with dedicated neonatal head coil.
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Table 2 HEAL MRI sequences and sequence parameters
Siemens (Prisma, Skyra, Verio, Trio) Philips (Achieva, Ingenia) GE (MR750, MR750w, Architect)
T1w (3D)
  Sequence MPRAGE 3D- TFE IR- SPGR
  Resolution 1×1×1 mm 1×1×1 mm 1×1×1 mm
  Slice orientation Sagittal Sagittal Sagittal
  TI 1100 ms 1000 ms 700 ms
  TE 3.05 ms 4.6 ms 3.16 ms
  TR 1550 ms 9.9 ms 8.15 ms
  Flip Angle 15 8 12
  Echo spacing* 9 ms 9.9 ms 8.36 ms
  Shot interval* 1550 ms 2000 ms 10.5 ms
  Bandwidth (pixel) 130 Hz 149 Hz 163 Hz
  Acceleration GRAPPA (none) SENSE (none) SENSE (none)
  Reformats Axial, Coronal Axial, Coronal Axial, Coronal
  TA 3:45 4:13 4:00
T2w (2D)
  Sequence TSE or BLADE TSE or MULTIVANE FSE or PROPELLER
  Resolution 1×1×2 mm 1×1×2 mm 1×1×2 mm
  TE ≥120 ms (target=160 ms) ≥120 ms (target=160 ms) ≥120 ms (target=160 ms)
  TR 10 000 ms 10 000 ms ≥7000 ms
  ETL 15 15 13
  Acceleration GRAPPA=2 SENSE=1.3 ASSET (≤2)
  TA 3:02 3:20 3:30
DTI
  Sequence Ep_2D DTI (‘High’) DTI (30- dir)
  Resolution 2×2×2 mm 2×2×2 mm 2×2×2 mm
  TE 81 ms 88 ms 88 ms
  TR 10 200 ms 10 000 ms 7500 ms
  No of Dir. 30 32 30
  Max b- value 1000 s/mm2 1000 s/mm2 1000 s/mm2
  Acceleration GRAPPA (2) SENSE (2.2) SENSE (2.2)
  TA 4:49 5:18 5:00
MRS
  Sequence SVS- SE PRESS PROBE
  Resolution 17×17×17 (Thal/BG) 17×17×17 (Thal/BG) 17×17×17 (Thal/BG)
15×15×15 (par. WM) 15×15×15 (par. WM) 15×15×15 (par. WM)
  TE 35 ms (short- echo) 35 ms (short- echo) 35 ms (short- echo)
288 ms (long- echo) 288 ms (long- echo) 288 ms (long- echo)
  TR 2000 ms 2000 ms 2000 ms
  Bandwidth 2000 Hz 2000 Hz 2000 Hz
  NSA (metabolite) 128 128 128
  NSA (water) 6 16 16
  TA 4:28 4:48 4:48
*Note that although all three vendors use an ultrafast gradient echo sequence, the IR- SPGR (GE) differs from the others with regard to the timing of 
the gradient echoes during acquisition, which prohibits direct comparisons between echo spacing and shot intervals across vendors.
3D, 3 dimensions; DTI, diffusion tensor imaging; ETL, echo train length; FSE, fast spin echo; GRAPPA, Generalized Autocalibrating Partially Parallel 
Acquisition; HEAL, high- dose erythropoietin for asphyxia and encephalopathy; IR- SPGR, Inversion prepped spoiled gradient echo sequence; NSA, 
Number of signal averages; SENSE, SENSitivity Encoding; TA, acquisition time; TE, echo time; TFE, Turbo Field Echo; TR, repetition time; TSE, turbo 

















pen: first published as 10.1136/bm





7Wisnowski JL, et al. BMJ Open 2021;11:e043852. doi:10.1136/bmjopen-2020-043852
Open access
both the total score and for the categorical classification 
(none, mild, moderate, severe). For the total score, we 
will use a general linear mixed effects model to estimate 
the intraclass correlation coefficient (ICC).67 For the cate-
gorical classification, we will use kappa.68 Secondary MRI 
measures include the MRI injury severity classification 
discussed above as well as classification of injury pattern 
and acuity. Injury pattern is classified as: (1) normal MRI 
(defined as no evidence of injury); (2) central (injury to 
the BGT±perirolandic cortex); (3) peripheral (injury to 
the parasagittal cortex and/or WM, ie, ‘borderzone/water-
shed distribution); (4) global (injury to BGT+ total or near 
total involvement of cortex±underlying WM); (5) punc-
tate WM Lesions (discrete foci of injury typically 1–10 mm 
in size localised to the periventricular WM or centrum 
semiovale); (6) arterial ischaemic stroke (infarct localised 
to the vascular territory of the middle, anterior or poste-
rior cerebral arteries); (7) other focal lesions (includes 
Figure 1 Representative HEAL MRI at the level of the PLIC obtained at each of the participating HEAL sites. Harmonisation 
centred on ensuring consistent sequences, sequence parameters and image resolution within and across participating 
sites. ADC, apparent diffusion coefficient; DTI, diffusion tensor imaging; HEAL, High- Dose Erythropoietin for Asphyxia and 
Encephalopathy.
Figure 2 Representative MR spectra acquired at each of the participating HEAL sites on the same patients as in figure 1. 
Note that two spectra were not available (n/a) from two patients above due to site- specific protocol constraints (top row) and 
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venous infarcts, contusions, and unilateral lesions to the 
BGT, cortex or white matter not classified elsewhere) and 
(8) atypical/not otherwise specified (with additional text 
field for describing the lesion). The scoring system allows 
for multiple patterns to be coded, which will allow us to 
determine the frequency of individual patterns as well as 
the co- occurrence across patterns.
Acuity is defined by the co- occurrence of signal abnor-
malities across the MRI sequences. Of note, the HEAL MRI 
examination occurs on day 4 or 5, prior to the expected 
pseudonormalisation of the ADC signal, and final analyses 
will be restricted to patients whose MRIs were completed 
within the first week. Acute lesions are defined as lesions 
that show correspondent diffusion restriction. Subacute 
lesions are defined as lesions (signal abnormalities) on 
T1w and/or T2w images without correspondent diffu-
sion restriction (high or ‘normal’ ADC signal). Chronic 
lesions are defined as lesions associated with volume loss 
and tissue remodelling (eg, porencephalic cysts). As for 
injury pattern, the scoring system permits coding multiple 
levels of acuity (eg, acute + subacute injury).
Data processing: MRS
The primary MRS outcome measure is the ratio of lactate 
to NAA. As secondary analyses, we will also determine 
lactate and NAA concentrations (mmol/kg) as well as 








RDA SPAR/SDAT P- file (Pxxxxx.7)
Preferred format 
for export
IMA Enhanced DICOM P- file (Pxxxxx.7)
Anonymisation During DICOM export During DICOM export Prior to export by way of pfile_anon 
(GE software)
Limitations Requires direct export to 
flash drive. If exporting to 
CD/DVD, anonymisation 
must be done manually
If scanner not configured to export 
enhanced DICOM, it may be necessary 
to export SPAR/SDAT, followed by 
manual anonymisation of SPAR file
If scanner not configured to allow 
for telnet access, P- file must be 
exported to DVD followed by manual 
anonymisation of P- file
CD, compact disc; DICOM, Digital Imaging and Communications in Medicine, which is the international standard to transmit, store, retrieve, 
print, process, and display medical imaging information; DVD, digital versitile disc.
Table 4 HEAL/Wash U MRI scoring system
T1 T2 Trace/ ADC




Cortex   
White Matter   
Brainstem   
Cerebellum   
Injury pattern(s):  ► Normal MRI (no evidence of injury)
 ► Central HIE Pattern (BGT±perirolandic cortex)
 ► Peripheral Pattern (Parasagittal cortex and/or WM, that is, ‘watershed’)
 ► Global Injury Pattern (BGT +total or near total involvement of cortex/WM)
 ► Punctate WM Lesions (discrete foci of injury (typically ~1 to 10 mm in size 
localised to the periventricular WM or centrum semiovale)
 ► Arterial Ischaemic Stroke
 ► Other focal lesion (includes venous infarct±IPH; contusion; unilateral lesions 
in BGT or other GM/WM not classified elsewhere)
 ► Atypical pattern (please specify:
Classification 
(independent of the 
scores above)


















pen: first published as 10.1136/bm





9Wisnowski JL, et al. BMJ Open 2021;11:e043852. doi:10.1136/bmjopen-2020-043852
Open access
additional MRS metabolites. Raw MRS data (ie, quan-
titative files, see table 3) are processed centrally under 
the direct supervision of SB and JLW using a modified 
LCModel (V6.3–1 L, Stephen Provencher, Oakville, 
Ontario, Canada) pipeline. This fully automated pipeline 
applies zero- order and first- order corrections for phase, 
estimates a baseline, corrects for ppm shift and eddy 
currents, and determines metabolite concentrations, all 
without need for user interaction. Data are fitted with 
linear combinations of model spectra of known concen-
tration from a standard basis set. For quantitation, the 
unsuppressed water signal is used as a concentration 
reference, with tissue water content estimated at a stan-
dardised value (ie, 86% or 47.8M) consistent with prior 
published methods.43 69
Statistical analyses
The primary neuroimaging outcome measures are: (1) 
the total injury score (derived from the HEAL/Wash U 
MRI scoring system above) and (2) the ratio of lactate/
NAA determined for the left thalamus and parietal white 
matter from the quantitative MRS data. For the MRI injury 
score and the lactate/NAA ratio, we will use linear regres-
sion to compare Epo treated patients to controls while 
adjusting for site and HIE severity since these are factors 
used to stratify the randomisation. In the event that we 
have missing data due to either early patient death or 
other factors (eg, family declines MRI or infant is unable 
to complete all of the sequences), we will estimate the 
resultant sampling bias by comparing our final neuroim-
aging sample to the overall HEAL sample with regard to 
patient demographics and primary outcome data.
Sample size
The sample size for the HEAL trial (n=500) is designed to 
yield greater than 90% power to detect a relative reduction 
in the rate of death or neurodevelopmental impairment 
(primary outcome) of 33% in the Epo group as compared 
placebo group.4 To calculate the sample size necessary for 
the secondary neuroimaging analyses, we first calculated 
the observed effect size for the MRI injury score for the 
prior phase II trial.7 This study demonstrated a lower 
brain injury score in Epo- treated infants as compared with 
placebo (mean 5.26±9.9 vs 16.36±18.3, p<0.01, Cohen’s 
d=0.75) and a lower rate of moderate/severe brain injury 
(4% vs 44%, p<0.002). Using a conservative effect size for 
HEAL (Cohen’s d=0.75/2) and controlling for multiple 
comparisons, a total sample size of 356 will yield greater 
than 90% power to detect a medium size effect (Cohen’s 
d=0.375) on brain injury as measured by the MRI injury 
score or lactate/NAA biomarker.
Neuroimaging harmonisation and quality assurance
The primary goal of harmonisation is to reduce measure-
ment error by maximising the consistency of neuroimaging 
data within and across sites. Minimising measurement 
error maximises the standardised effect size and there-
fore statistical power.70 Intrasite and intersite variability in 
MRI measurements can arise due to variability in: (1) MR 
hardware (eg, field strength, gradient strength, sensitivity 
of the head coils, hardware upgrades); (2) software (eg, 
sequences, sequence parameters, software upgrades); (3) 
patient workflow (eg, whether an infant is sedated or fed/
swaddled in an infant immobiliser; whether the infant is 
properly positioned in the centre of the head coil) and 
(4) the timing of the MRI (eg, before or after expected 
pseudonormalisation of the diffusion signal). Addition-
ally, noncompliance, a common challenge in multisite 
studies, contributes further error. Although it is possible 
to include ‘site’ as a covariate in statistical models, site 
and scanner effects are often non- linear and non- uniform 
across the brain as well as sequence- specific, making 
them challenging to manage retrospectively using statis-
tical techniques. Accordingly, managing harmonisation 
prospectively through study design and real- time moni-
toring are key to ensuring the reliability and reproduc-
ibility of the neuroimaging biomarkers.
Our harmonisation efforts for HEAL centre on two 
areas: (1) a certification process to ensure that each site 
was able to obtain high- quality data in accordance with 
the HEAL protocol and (2) a robust quality assurance 
process designed to monitor acquisition and mitigate 
errors in a timely fashion throughout the trial. Prior to 
the start of HEAL, we developed a standardised MRI/S 
protocol and verified that it could be carried out across 
platforms to generate resultant images that were compa-
rable across platforms with regards to tissue contrast, reso-
lution and SNR. Because the HEAL MRIs are acquired as 
part of standard clinical care, as part of site initiation, we 
had discussions with at least one neuroradiologist from 
each site, as well as site PI, to ensure that the proposed 
HEAL MRI/S protocol would meet the site’s require-
ments for a clinical MRI protocol and to mitigate any site- 
specific challenges implementing the HEAL protocol. 
Additionally, each site provided a test dataset, which were 
used to verify sequence parameters, image homogeneity, 
slice orientation and motion. MRS data were reviewed 
for voxel position and raw data was processed to ensure 
adequate line width and SNR. Furthermore, the test scans 
certified the data transfer process and ensured that all 
data, including raw MRS, could be captured from each 
site and transferred to the HEAL Neuroimaging Core.
During the enrolment period, quality assurance is 
maintained through a real- time process aimed at moni-
toring acquisition and mitigating any protocol deviations. 
All brain MRI and MRS data are reviewed shortly after 
being uploaded to the HEAL database. Any protocol devi-
ations are recorded and each sequence (T1w, T2w and 
DTI) is scored for motion on a four- point scale: none, 
mild (unlikely to affect interpretation), moderate (may 
affect interpretation), severe (obfuscates interpretation). 
Likewise, MRS sequence parameters and voxel positions 
are reviewed, and raw data are checked to ensure that 
valid files are present for MRS processing. All protocol 
deviations and severe motion or other artefacts are imme-
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Phantom studies
The primary HEAL MRI and MRS endpoints, namely the 
total MRI injury score and the ratio of lactate/NAA, were 
designed to be robust across a wide range of scanner 
platforms. However, to take full advantage of potential 
secondary analyses, including quantitative MRS and DTI 
biomarkers, we are carrying out additional phantom studies 
during the HEAL trial. These phantoms studies are aimed at 
further reducing unwanted site- related and scanner- related 
variance from our quantitative MRS and DTI measures. For 
MRS, we are using a commercially available phantom (GE 
Healthcare), which contains physiological concentrations of 
NAA, lactate, creatine, choline, glutamate and myoinositol. 
For DTI, we are using the diffusion ice- water phantom, 
which leverages the known properties of water diffusion at 
0°C.71 Both phantoms will be scanned on multiple days at the 
HEAL neuroimaging core and twice within a single session 
at participating HEAL sites using the HEAL MRS and DTI 
protocols. We will use these data to compute the coefficient 
of variation for each metabolite concentration and ADC 
value across MR vendors, platforms and sites. These data will 
not only provide an estimate of the degree of measurement 
error that is attributable to scanner and site- specific effects, 
but also help to inform whether we will need to deploy addi-
tional retrospective statistical approaches (eg, ComBat72) to 
address unwanted site- related and scanner- related variance.
Unfortunately, we could not identify comparable phan-
toms with appropriate T1 and T2 values for an infant 
brain and employing a ‘travelling infant’ as a phantom 
was impractical. Thus, further harmonisation of the T1w 
and T2w data will have to be carried out using retrospec-
tive statistical approaches.
DISCUSSION
The search for new neuroprotective therapies is ongoing, 
not only for neonatal HIE, but also a range of disorders, 
including stroke, traumatic brain injury and cardiac 
arrest. As preclinical studies identify promising thera-
pies, the research community needs reliable biomarkers 
with which to move promising therapies from phase II to 
phase III trials. This is critical, given the scarce resource of 
appropriate patients and the cost of clinical trials. Neuro-
imaging biomarkers can help facilitate clinical translation 
by providing early endpoints for evaluating treatment 
efficacy. Furthermore, they can be used to elucidate treat-
ment effects and the mechanisms by which improvements 
in neurological outcomes are achieved.
At the same time, ensuring the reliability and reproduc-
ibility of neuroimaging data across a large- scale, multisite 
RCT remains challenging. As a field, some of these chal-
lenges could be mitigated by adopting common protocols 
for neuroimaging. This would not only aid in the repro-
ducibility within and across trials, but also strengthen 
research from bench to bedside by providing a means for 
directly comparing the effects of therapies in preclinical 
and clinical trials to those obtained in clinical practice. 
Last, some of the technological challenges, such as MRS 
data transfer and storage, would be eliminated if manu-
facturers were to use the standard DICOM format for 
archiving MRS data, as was done for conventional MRI 
more than three decades ago.
Summary
HEAL is the first phase III RCT for neuroprotection to 
incorporate MRI, DTI and MRS biomarkers on a large scale. 
We present standardised MRI and MRS protocols for HIE 
that are feasible on any modern 3T platform and describe 
our rigorous quality assurance procedures. Using phantom 
studies, we will characterise the degree of unwanted site- 
specific and scanner- specific effects remaining after harmon-
isation, which, in turn, will be used to estimate the need 
for advanced statistical methods to reduce such nuisance 
variance. Together, these methods will ensure rigour and 
reliability of the neuroimaging biomarkers collected in 
the HEAL trial and may help inform the design of future 
neonatal neuroprotection trials.
ETHICS AND DISSEMINATION
The study protocol (currently: V.2.9, 18 March 2020), site- 
specific informed consent forms, participant education 
and recruitment materials and all study modifications 
have been approved by the local Institutional Review 
Board at each of the participating sites. Parents have 
provided written permission for their child’s participa-
tion in the HEAL trial. Safety and progress reports are 
provided to the NIH- appointed data safety monitoring 
committee every 6 months.
Study findings will be disseminated through scientific 
conferences, peer- reviewed journal publications, public 
study website materials and invited lectures. Results from 
this study will be reported according to SPIRIT guide-
lines65 and submitted for peer- reviewed publication. 
Individual participant data, including neuroimaging 
data, will be made available through the National Insti-
tute of Neurological Disorders and Stroke (NINDS) Data 
Archive: https://www. ninds. nih. gov/ Current- Research/ 
Research- Funded- NINDS/ Clinical- Research/ Archived- 
Clinical- Research- Datasets. The data will be deidentified 
and a limited access data set will be available after March 
2024 through a request form on that page. Data dictio-
naries, in addition to study protocol, the statistical anal-
ysis plan and the informed consent form will be included.
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